Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.44 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | CTSS | P25774 | 2/20 | 0.41 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.41 |
| ▸ | WNT3A | P56704 | 1/20 | 0.41 |
| ▸ | F2R | P25116 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6695536 | 1.00 | LMNA (0.44) | LMNAGAAKCNK3KCNK9TSHR | |
| SCHEMBL7326089 | 0.82 | TSHR (0.42) | LMNAGAAKCNK3KCNK9TSHR | |
| SCHEMBL13183353 | 0.80 | LMNA (0.49) | LMNAGAACTSSCTNNB1WNT3A | |
| SCHEMBL1994129 | 0.76 | TSHR (0.67) | LMNAGAAKCNK3KCNK9TSHR | |
| SCHEMBL3293086 | 0.75 | MAPT (0.49) | LMNAGAATSHRKDM4EKMT2A | |
| SCHEMBL3293089 | 0.75 | MAPT (0.49) | LMNAGAATSHRKDM4EKMT2A | |
| SCHEMBL6695543 | 0.75 | NPSR1 (0.49) | GAAMAOBKDM4EKMT2AEPHX2 | |
| SCHEMBL10399182 | 0.75 | LMNA (0.41) | LMNAGAAKCNK3KCNK9TSHR | |
| SCHEMBL10399181 | 0.75 | LMNA (0.41) | LMNAGAAKCNK3KCNK9TSHR | |
| SCHEMBL401715 | 0.74 | LMNA (0.49) | LMNAGAAKCNK3KCNK9TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6833374-B2 | Such as 2-(4-chlorophenyl)-4-(3-(trifluoromethyl)phenyl)-1,2-dihydro-3H-pyrazolo(3,4-d)thieno(2,3-b)pyridin-3-one; for immunotherapeutic treatment of transplant rejection, autoimmune diseases, or graft versus host disease | WYETH | 2004-12-21 | — | — | US | disclosed |
| US-6734190-B2 | REGULATION OF T CELL RESPONSES FOR IMMUNOSUPPRESION | WYETH | 2004-05-11 | — | — | US | disclosed |
| US-20040024008-A1 | Dihydrodipyrazolopyridinylbenzamide and -sulfonamide inhibitors of B7-1 | WYETH | 2004-02-05 | — | — | US | disclosed |
| US-20040024009-A1 | Dihydropyrazolo[3,4-d]thieno-[2,3-B]pyridinone inhibitors of B7-1 | WYETH | 2004-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040024009-A1 | Dihydropyrazolo[3,4-d]thieno-[2,3-B]pyridinone inhibitors of B7-1 | CD274, PDCD1, PDCD1LG2 | LMNA 4829/4885GAA 4221/4885KCNK3 806/4885 |
| US-20040024008-A1 | Dihydrodipyrazolopyridinylbenzamide and -sulfonamide inhibitors of B7-1 | CD274, PDCD1, VCAM1 | LMNA 4861/4885GAA 3043/4885KCNK3 676/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.